Maybe I can start, and Iain can chime in.
Moderna becomes the workhorse of the portfolio in Q3. There's a big Q3 ramp up. We are waiting for a revised schedule from Moderna, because I think it's been well document that Moderna has hit a bit of a bump in production. We should have clarity on what the schedule looks like for June and July in the next week or so.
I apologize, Mr. Chair, as I can't give you a firm number on expectations for Moderna in total for June and July, but we should have a better sense after next week.